Bristol Myers Squibb stock extends Camzyos evidence in adolescents

Bristol Myers Squibb presented 56-week results from the Phase 3 SCOUT-HCM trial on Friday, November 6, at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago. The company said the data extend evidence for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

The stock later traded at 55.50 euros on Lang & Schwarz at 16:13 CET on Monday, November 9, 2026. That quote was 1.58 percent below the 56.39 euros cited in the earlier report at 12:42 CET the same day, a separate comparison from the Xetra daily close.

What changed for Camzyos

SCOUT-HCM randomized 44 patients aged 12 to under 18, with 43 completing the initial 28-week placebo-controlled period and continuing into active treatment. Patients who received mavacamten throughout the study recorded a mean change from baseline of minus 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks.

Patients who switched from placebo to Camzyos at week 28 achieved a similar reduction. The trial also reported meaningful improvements in several secondary endpoints, according to the Bristol Myers Squibb investor release.

Why it matters for investors

No patient experienced a left ventricular ejection fraction below 50 percent during the 56-week evaluation. The continuous-treatment group recorded five treatment-related adverse events and two serious events, while the crossover group recorded one treatment-related event and no serious event during its active-treatment period.

The U.S. Food and Drug Administration approved Camzyos for pediatric patients weighing at least 30 kilograms in September 2026. The expanded follow-up strengthens the evidence base for a newly eligible patient segment, although the small trial population and continuing safety monitoring remain relevant to expectations for uptake.

The company planned additional Camzyos presentations covering clinical and real-world evidence at the American Heart Association Scientific Sessions through Monday, November 9.

The S&P 500 provides the broader market backdrop for the U.S.-listed pharmaceutical company.

More news and analyses on Bristol Myers Squibb stock cover subsequent pipeline, regulatory and financial developments.